Cancer patients who got a COVID vaccine lived much longer

A groundbreaking study has revealed that individuals battling advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of initiating immunotherapy experienced a significantly extended lifespan compared to those who did not. This pivotal research, presented today, October 19, 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, marks a potential turning point in oncology, building upon more than a decade of dedicated work in mRNA-based treatments designed to activate the body’s intrinsic immune defenses against cancer. The findings represent a crucial step toward developing a universal cancer vaccine capable of dramatically enhancing the efficacy of existing immunotherapies.

A Decade of mRNA Research Culminates in Unexpected Discovery

The roots of this potentially revolutionary discovery trace back to extensive research at the University of Florida (UF) and the University of Texas MD Anderson Cancer Center. Scientists have long explored the potential of messenger RNA (mRNA), the ubiquitous molecule present in every cell that carries instructions for making proteins, to program the immune system to target cancerous cells. This latest analysis, while preliminary, involved a comprehensive review of medical records from over 1,000 MD Anderson patients, offering compelling evidence for the unexpected immune-boosting effects of COVID-19 mRNA vaccines in a cancer context.

The journey toward this insight accelerated significantly in July of this year, when senior researcher Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, and his laboratory made an unanticipated discovery. They found that to trigger a robust immune attack on cancer, it wasn’t strictly necessary to target a specific tumor protein. Instead, merely stimulating the immune system to react as if it were combating a viral infection could elicit a powerful antitumor response. This experimental "nonspecific" mRNA vaccine, utilizing technology similar to that of COVID-19 vaccines but not targeting any specific virus or cancer, was then paired with immune checkpoint inhibitors—a class of common cancer drugs that effectively "release the brakes" on the immune system, allowing it to recognize and destroy tumors more effectively. In mouse models, this combination yielded a potent and encouraging antitumor effect.

This breakthrough sparked a critical question from former UF researcher and current MD Anderson scientist Adam Grippin, M.D., Ph.D.: Could the widely administered COVID-19 mRNA vaccine, which employs similar immunological principles, have a comparable immune-boosting effect in human cancer patients? The subsequent investigation into this hypothesis led to the observational study presented at ESMO.

Observational Study Reveals Striking Survival Gains

To investigate Grippin’s hypothesis, the research team meticulously analyzed data from patients diagnosed with Stage 3 and 4 non-small cell lung cancer and metastatic melanoma who received treatment at MD Anderson between 2019 and 2023. The study specifically focused on patients who received a COVID-19 mRNA vaccine within 100 days of initiating immunotherapy, comparing their outcomes to those who did not.

The findings were remarkable. For advanced lung cancer patients, receiving an mRNA COVID-19 vaccine was associated with a near doubling of median survival. Among 180 advanced lung cancer patients who received a COVID vaccine within the specified 100-day window (either before or after starting immunotherapy), the median survival extended to 37.3 months. This stands in stark contrast to the 704 patients treated with the same immunotherapy drugs who did not receive the vaccine, whose median survival was 20.6 months.

Similarly, for patients with metastatic melanoma, the results were equally impressive. Of the 43 metastatic melanoma patients who received a vaccine within 100 days of initiating immunotherapy, their median survival increased from 26.7 months to a range of 30 to 40 months. Notably, at the time of data collection, some of these patients were still alive, suggesting the potential for an even stronger, yet unquantified, long-term survival benefit. This was compared to 167 melanoma patients who did not receive a vaccine.

Crucially, the study also provided a control against other types of vaccines. Receiving non-mRNA vaccines, such as those for pneumonia or influenza, showed no comparable changes in longevity, underscoring the specific role of mRNA technology in these observed benefits. According to Dr. Sayour, the most significant improvements were observed in patients who, based on their tumor biology and other clinical factors, were not initially expected to respond strongly to immunotherapy. This suggests that the mRNA vaccine might be recruiting an immune response in patients who otherwise have exhausted other options.

Expert Commentary and Enthusiasm for a "Universal" Vaccine

The implications of these findings have resonated deeply within the scientific and medical communities. "The implications are extraordinary — this could revolutionize the entire field of oncologic care," stated Dr. Sayour. He further elaborated on the long-term vision: "We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients." This prospect offers immense hope for democratizing advanced cancer treatment, making it accessible and effective for a broader patient population.

Jeff Coller, Ph.D., a leading mRNA expert at Johns Hopkins University, emphasized how these results highlight the far-reaching benefits of Operation Warp Speed, the U.S. government’s rapid COVID-19 vaccine initiative. "The results from this study demonstrate how powerful mRNA medicines truly are and that they are revolutionizing our treatment of cancer," Coller noted, acknowledging the "unique and unexpected ways" the accelerated development of mRNA technology during the pandemic continues to benefit lives.

Duane Mitchell, M.D., Ph.D., Grippin’s doctoral mentor and director of the UF Clinical and Translational Science Institute, echoed the sentiment of profound impact. "Although not yet proven to be causal, this is the type of treatment benefit that we strive for and hope to see with therapeutic interventions — but rarely do," Mitchell remarked. He stressed the urgency of further research: "I think the urgency and importance of doing the confirmatory work can’t be overstated."

The Science Behind the Effect: A "Flare" for Immune Cells

While the exact mechanisms are still under investigation, researchers propose that the mRNA vaccine acts as a potent immune stimulant, effectively recalibrating the body’s defenses. Dr. Sayour explained, "One of the mechanisms for how this works is when you give an mRNA vaccine, that acts as a flare that starts moving all of these immune cells from bad areas like the tumor to good areas like the lymph nodes." This "flare" effect could potentially awaken dormant immune responses or enhance the activity of immune cells that were previously unable to effectively target the cancer.

To further substantiate their observational findings, UF researchers conducted additional experiments using mouse models. They paired immunotherapy drugs with an mRNA vaccine specifically targeted at the COVID spike protein. These experiments provided crucial preclinical validation, demonstrating that the combination could successfully transform unresponsive cancers into responsive ones, effectively thwarting tumor growth. This laboratory confirmation strengthens the hypothesis that the immune activation triggered by the mRNA vaccine is a key factor in improving therapeutic outcomes.

Broader Implications and The Path Forward

Despite the compelling nature of these preliminary findings from an observational study, researchers are quick to emphasize the need for confirmation through rigorous randomized clinical trials. Such trials are the gold standard for establishing causality and determining the true efficacy and safety of new interventions.

The next critical step involves launching a large-scale clinical trial through the UF-led OneFlorida+ Clinical Research Network. This extensive consortium, encompassing hospitals, health centers, and clinics across Florida, Alabama, Georgia, Arkansas, California, and Minnesota, is ideally positioned to conduct the necessary confirmatory work. "One of our key motivations at OneFlorida is to move discoveries from academic settings out into the real world and the places where patients get care," said Betsy Shenkman, Ph.D., who leads the consortium, highlighting the network’s commitment to translating groundbreaking research into tangible patient benefits.

If confirmed, these findings unlock numerous possibilities for the future of cancer treatment. The potential to design an even more effective "nonspecific universal vaccine" holds immense promise. For patients suffering from advanced cancers, where treatment options are often limited and prognosis grim, the increased survival afforded by such a universal vaccine would be an invaluable gift – more time with loved ones, more opportunities for life. "If this can double what we’re achieving currently, or even incrementally — 5%, 10% — that means a lot to those patients, especially if this can be leveraged across different cancers for different patients," said Dr. Sayour, an investigator with UF’s McKnight Brain Institute.

The development of a universal, off-the-shelf cancer vaccine would represent a paradigm shift in oncologic care. It could simplify treatment regimens, potentially reduce costs associated with highly personalized therapies, and offer a broad-spectrum approach to boosting the immune system against various cancer types. The economic and accessibility implications for global cancer care could be profound, particularly in regions where advanced personalized treatments are scarce.

The study was funded by critical support from the National Cancer Institute and multiple foundational grants, underscoring the collaborative effort behind this research. Furthermore, transparency regarding intellectual property is maintained, with Sayour, Grippin, and Mitchell holding patents related to UF-developed mRNA vaccines that are licensed by iOncologi Inc., a biotech company spun out from UF in which Mitchell holds an interest. This highlights the ongoing commitment to translating academic discoveries into viable therapeutic options. The medical community and patient advocacy groups alike are keenly awaiting the results of the confirmatory trials, hopeful that this unexpected benefit of mRNA technology will indeed usher in a new era of cancer treatment.